Today, at the Kazakh Invest site, a long-term contract for the supply of the original patented drug was signed with the pharmaceutical giant AstraZeneca.
From AstraZeneca, the meeting was attended by Zhalgas Daniyarov, Manager of Government Relations and Public Relations, and Andrey Ivanov, Director of Market Access. The event was also attended by the Stephen Brennan, Deputy Director of the Department of Business and Trade at the British Embassy, Chairman of the Board of JSC NC KAZAKH INVEST Yerzhan Elekeev, Managing Director of Task Force Azamat Kozhanov.
Among the representatives of the Ministry of Health of the Republic of Kazakhstan are Director of the Department of Development of the Pharmaceutical and Medical Industry of the Ministry of Health of the Republic of Kazakhstan Aslan Kinayatov, Adviser to the Minister of Health on Pharmaceutical and Medical Industry Galym Amreev. Acting Chairman of the Board Ruslan Nurmukhanov and Executive Director Askhat Mubarakov took part from SK-Pharmacy.
To attract foreign investors to the pharmaceutical industry of Kazakhstan, a Memorandum of Cooperation was signed between SK-Pharmaceuticals and Kazakh Invest. Within the framework of the document, the parties support initiatives on the implementation of investment projects.
«Today, we are witnessing the signing of a Long-term Agreement between «AstraZeneca» and SK-Pharmaceuticals, which gives a positive impetus to the implementation of the investment project for the contract production of biotechnological drugs. I would also like to note the active involvement in this process of the Investment Headquarters under the Government of the Republic of Kazakhstan, at which issues related to pharmaceutical companies were repeatedly discussed, a number of projects of «BigPharm» companies, which in turn grew into separate cases like «AstraZeneca» - said the Chairman of the Management Board of JSC «NC «KAZAKH INVEST» Erzhan Elekeev.
This agreement is an important step in the development of long-term cooperation and is aimed at ensuring a stable and high-quality supply of necessary medicines.
The British-Swedish pharmaceutical company AstraZeneca is one of the largest pharmaceutical companies in the world. AstraZeneca's product portfolio includes drugs in therapeutic areas such as cardiology, pulmonology, nephrology, metabolism, respiratory and autoimmune diseases, oncology and rare diseases.
As part of the concluded long-term agreement, AstraZeneca intends to establish contract manufacturing in the Republic of Kazakhstan, ensuring full compliance with the requirements of good manufacturing practice (GMP) and organize the supply of original patented medicines produced in Kazakhstan.
Director of AstraZeneca Kazakhstan Maria Shipuleva: “Today we signed an important agreement with SK-Pharmaceuticals, which reflects our company’s plans for the production of medicines in Kazakhstan. AstraZeneca's innovative drugs will be produced at the site of the domestic manufacturer - Nobel Almaty Pharmaceutical Factory JSC. In particular, it is planned to contract production of drugs for the treatment of diabetes mellitus, chronic heart failure, chronic kidney disease, for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma, for the treatment of ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, as well as for the treatment of non-small cell cancer of a lungs. We hope that our activities under a long-term agreement with SK-Pharmaceuticals will help further the development of the country’s healthcare system, and most importantly, improve the quality of life of our Kazakhstani patients.”
This important step will help increase the availability of high-quality medicines for patients in Kazakhstan.
The Unified Distributor takes an active position in the development of cooperation in the field of pharmaceuticals between Kazakhstan and Sweden, initiating a number of bilateral meetings to consider ways of partnership. And today’s conclusion of a long-term agreement was the result of all previous agreements and close interaction with one of the leading pharmaceutical companies, AstraZeneca.
“We, as a Unified Distributor, express our full readiness to perform our functions under the Long-Term Agreement and continue comprehensive work on the dynamic development of the industry, including attracting BigPharma to the domestic pharmaceutical market,” said the Acting Chairman of the Management Board of SK-Pharmaceuticals LLP Ruslan Nurmukhanov.
It is expected that cooperation with AstraZeneca will bring innovation and the latest scientific developments to the pharmaceutical industry of Kazakhstan, as well as improve the qualifications of Kazakh specialists through the exchange of experience.
It is worth noting that previously long-term contracts had already been signed with such global industry players as Pfizer and Roche. The signing took place within the framework of the key investment event in the country - the Kazakhstan Round Table on Global Investment.
.jpeg)